Delcath Systems (DCTH) Reports Q2 Loss of $0.30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Delcath Systems (DCTH) Reports Q2 Loss of $0.30
August 5, 2015 8:00 AM EDT
NEW YORK, Aug. 5, 2015 /PRNewswire/ --Â Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2015.Â
Highlights of the second quarter and recent weeks included:
Quarterly product revenue of $0.5 million, an increase of nearly 85.7% compared with the second quarter of 2014
Total operating expenses decreased by 35.1% to $4.0 million from $6.1 million in the second quarter of 2014
Enrollment opened for an...
More
August 4, 2015 8:00 AM EDT
NEW YORK, Aug. 4, 2015 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that two abstracts summarizing data from studies in Europe and the U.K. of treatment with the Delcath Hepatic CHEMOSAT® Delivery System (CHEMOSAT) will be presented at the upcoming European Association of Dermato Oncology (EADO) annual congress, which will be held in Marseille, France, October 28-31, 2015.
The abstracts are:
Treating Unresectable Liver...
More
